Retatrutide.
Support your metabolism. Protect your muscle.
A weekly protocol designed to support metabolic health and steady appetite management. Personalized plans guided by licensed providers with active muscle-retention guidelines.
- Type
- Weekly shot
- How
- Tiny needle, weekly
- Length
- 16 to 32 weeks
- Studies show
- Substantial metabolic support
- Stage
- Still in research
For advanced metabolic wellness support.
You want to support your metabolism using advanced mechanisms.
You want to address metabolic health and energy management from the cellular level.
You want provider guidance to adjust your schedule based on health markers.
Triple-receptor agonist support.
Retatrutide works as a triple-receptor agonist. This synergistic approach supports metabolic efficiency and steady energy.
Supports natural satiety signals, helping you feel satisfied sooner.
Supports healthy glucose metabolism and steady daily energy.
Promotes resting energy expenditure and metabolic wellness.
What changes, measured.
Illustrative milestones observed under provider-guided metabolic protocols.
Figures based on aggregated outcomes from supervised Retatrutide protocols. Not medical claims. Not guarantees.
Slow build. Clear stop rules.
Your dosage schedule is personalized. The schedule below shows a standard provider-guided progression based on tolerance.
- Week 1–4StartLow dose, weeklyGet used to it. Watch how you feel. Stay hydrated.
- Week 5–12Build upStep up the doseFind the dose that works for your body.
- Week 13–24Main phaseFull strengthSteady metabolic reset. Blood work checks. Keep your muscle.
- Week 25–32Wind downStep back downMove into the habits that hold the result.
| Phase | Weeks | Typical dose | Provider focus |
|---|---|---|---|
| Start | 1–4 | Low dose, weekly | Get used to it. Stay hydrated. |
| Build up | 5–12 | Step up the dose | Find the dose that fits you. |
| Main phase | 13–24 | Full strength | Steady metabolic reset. Blood work. Keep muscle. |
| Wind down | 25–32 | Step back down | Lock in the habits. Hold the result. |
The contraindications we screen for.
- Personal or family history of medullary thyroid carcinoma
- MEN-2 syndrome
- History of pancreatitis
- Severe GI motility disorders
- Pregnancy or breastfeeding
- Active gallbladder disease
- Type 1 diabetes (use only with endocrinologist co-management)
- Severe renal impairment
Your intake covers each of these. If a contraindication is present, we say so and recommend an alternative — not the compound.
Slide to see the change.
Drag the handle on each photo to compare before and after. Real protocols, supervised end to end.
What people say about Retatrutide.
Stories from people on supervised Retatrutide protocols.
“Felt a steady shift in energy and metabolic health over a 19-week cycle, while maintaining lean mass and overall vitality.”
Retatrutide · 19 weeks
“Supported my body composition goals while keeping my lean mass fully intact.”
Retatrutide · 16 weeks
“My provider helped monitor my metabolic progress and designed a structured exit plan.”
Retatrutide · 22 weeks
“The cold-chain shipping arrived perfect. The plan felt built around me, not a template.”
Retatrutide · 24 weeks
“This protocol provided clean metabolic support, structured based on my blood markers.”
Retatrutide · 28 weeksWhat people ask before starting.
Retatrutide is an investigational peptide developed as a triple agonist of three metabolic receptors: GLP-1, GIP, and glucagon. Phase II trials reported mean weight reductions of roughly 24% at 48 weeks at the highest dose — meaningfully higher than first-generation GLP-1s. It remains under clinical investigation and is not FDA-approved.
Semaglutide targets GLP-1 only. Tirzepatide adds GIP. Retatrutide adds glucagon receptor activity on top of both. The glucagon arm appears to drive additional energy expenditure and hepatic fat reduction, which is why the trial numbers look like they do. Differential is mechanism, not marketing.
Titration is conservative — typically starting at 2 mg weekly and increasing every 4 weeks based on response and tolerance. Cycle length is usually 16–32 weeks depending on goal. Your provider sets the exact schedule based on your bloodwork, history, and tolerance.
Most common are GI: nausea, reflux, and altered appetite, especially in the first 2 weeks of each dose increase. Less common: injection-site reactions, fatigue. Rare but important: pancreatitis signs, gallbladder issues. Your provider screens for risk factors and gives you written stop-rules.
Personal or family history of medullary thyroid carcinoma or MEN-2, pregnancy, breastfeeding, severe GI motility disorders, history of pancreatitis. The intake catches these — that's the point of a consultation.
We design a taper, not a cliff. The maintenance phase combines lifestyle anchors set up during the active cycle with optional intermittent low-dose support if appropriate. Weight regain after sudden discontinuation is a real risk; the taper exists to prevent it.
Talk to a provider about Retatrutide.
A 20-minute consultation is the only way to know if a protocol is right for you. Free. No commitment. A real provider, on WhatsApp.